Open access peer-reviewed Edited Volume

Immune Checkpoint Inhibitors - New Insights and Recent Progress

Afsheen Raza

Hamad Medical Corporation

Dr. Raza has been trained in Cancer Biology and Therapeutics at Harvard Medical School, USA, and in Molecular Biology at Aga Khan University. She has more than 10 years of research experience and 30+ peer-reviewed publications in high-impact journals. She serves as Academic Editor for the PLOS ONE Journal and has acted as a reviewer for several journals including the Journal of Translational Medicine, the Journal of Cancer Management and Research, and the Journal of Cancer Drug Resistance.


Inhibitory Receptors NK Cells Activating Receptors Tumor Immune Escape Cancer Immunotherapy Mechanisms of Targeting Checkpoint Cells Targeting Clinical Trials Biomarkers Immune Checkpoint Cells Immune Checkpoint Inhibitors Future Perspectives

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

Immune checkpoint inhibitors (ICI) such as anti-PD-1 and anti-PD-L1 are major FDA-approved monoclonal antibodies that are utilized for many hard-to-treat cancers. Though these drugs have shown progression-free survival in many cancer types, the patient response to ICI is still low i.e. <40% indicating that several immune checkpoint molecules within the tumor microenvironment are playing a role in the respective treatment dynamics. Of these, Natural killer (NK) cells immune checkpoint molecules are emerging as new targets of therapy. Several NK receptors and immune checkpoints have been documented to play a role in immune escape and tumor progression. Therefore, identification and targeting of NK immune checkpoint molecules to restore cell cytotoxicity and induction of robust anti-tumor response is an area of cutting-edge research globally. On the other hand, the identification of NK markers as potential predictive and prognostic biomarkers can serve as an important tool for the stratification of patients on immunotherapy. Therefore, knowledge on NK cell-based immune checkpoints can pave the way for personalized cancer therapeutics.

Publishing process

Book initiated and editor appointed

Date completed: March 16th 2022

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline for chapter proposals: May 25th 2022

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Register for the book

Approved chapters written in full and submitted

Deadline for full chapters: July 24th 2022

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: October 12th 2022

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: December 11th 2022

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Afsheen Raza

Hamad Medical Corporation

Dr. Afsheen Raza is a research scientist with extensive experience in cutting-edge molecular biology/immunology research and cancer clinical trials currently working at the Translational Cancer Research Institute of National Center of Cancer Care and Research (NCCCR) and Hamad Medical Corporation, Qatar. She is trained in Cancer Biology and Therapeutics at Harvard Medical School, USA, and in Molecular Biology at Aga Khan University. She has extensive experience in conducting large study grants and clinical trials. Her primary research focuses on studying tumor-host immune interactions to immunotherapeutic strategies and is also engaged in establishing immune-monitoring platforms/analytical tools to evaluate novel immune-modulators and cancer antigen-specific immune cells that will serve as a foundation for translational research. Apart from 10 years of research experience and 39+ peer-reviewed publications in high-impact journals, Dr. Raza has authored a book chapter and is a reviewer for several journals. She is Internationally recognized for her scientific contribution to cancer immunology and immunotherapy – Academic Editor for PLOS ONE journal, Guest Editor for prestigious journal of Frontiers in Immunology and Special Collection in Biomarker Insight for SAGE Publishing. She has six years of experience in mentoring and supervising Masters and Ph.D. students in their research projects and in teaching immunology and molecular biology curriculum and lab techniques to rotating clinical fellows from Hematology, Immunology, and Allergy programs. h-index=14 , ORCID ID: 0000-0002-0264-3304

View profile

Book chapters authored 1

Books edited 0

Introducing your Author Service Manager

Ms. Marina Dusevic

As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question

Book will be abstracted and indexed in